---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000004"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:51.083213+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV

## Summary
- Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.
- 2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.
- LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).
- Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.
- Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026.

## SEC filing metadata
- accession: 0001759425-26-000004
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/0001759425-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000004/mirm-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000004
- JSON: https://secwatch.observer/filing/0001759425-26-000004.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.